Clinical recommendations

Primary colon cancer: ESMO Clinical Recommendations for diagnosis, adjuvant treatment and follow-up

E. Van Cutsem & J. Oliveira
On behalf of the ESMO Guidelines Working Group*

1Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; 2Service of Medical Oncology, Portuguese Institute of Oncology, Lisbon, Portugal

Incidence

In 2006 there were 412,900 new cases of colorectal cancer in Europe. This is 12.9% of all cancer cases. Colorectal cancer was responsible for 217,400 deaths in Europe in 2006. This represents 12.2% of all cancer deaths.

Diagnosis

The diagnosis of a colonic adenocarcinoma requires a histopathologic confirmation taken via colonoscopy/sigmoidoscopy. Risk factors including familial and/or hereditary predisposition, location, and histological evaluation of colonic tumors should be documented.

Staging and Risk Assessment

Staging provides essential prognostic information relevant for choosing adequate therapy and should also identify patients with resectable distant metastases.

Preoperative staging consists of clinical examination, blood counts, liver and renal function tests, carcino-embryonic antigen (CEA), chest X-ray or preferably chest CT-scan, CT scan of the abdomen including the pelvis and a colonoscopy of the entire large bowel, i.e. with postoperative repeat colonoscopy if proximal parts of the colon were not accessible preoperatively.

Pathologic staging should be done according to the 2002-TNM system with optional listing of the modified Dukes stage, as described in Table 1.

Risk factors for colorectal cancer are: family history, familial adenomatous polyposis (FAP) and attenuated FAP (AFAP) syndromes, hereditary non-polyposis colorectal cancer (HNPPC) syndrome, past history of colorectal cancer or adenoma, chronic ulcerative colitis and Crohn’s disease.

Prognosis

Survival rates have been published from the SEER US national cancer registry from January 1, 1991 through December 31, 2000 based on data from 199,363 patients according to the new AJCC sixth edition staging. Overall 5-year colon cancer-specific survival for this entire cohort was 65.2%. Five-year colon cancer-specific survival by stage was 93.2% for stage I, 84.7% for stage IIa, 72.2% for stage IIb, 83.4% for stage IIIa, 64.1% for stage IIIb, 44.3% for stage IIIc and 8.1% for stage IV cancer. Another large analysis based on the US National Cancer database showed in 50,042 patients from 1987 till 1993 a 5-year survival rate of 59.8% for stage IIIa, 42.0% for stage IIIb and 27.3% for stage IIIc colon cancer.

Treatment

Surgery is the mainstay in the management of patients with colon cancer. The primary goal is a wide resection of the primary tumor with all locoregional lymph nodes. Optimal surgery by experienced colorectal surgeons should be performed. An adequate number of lymph nodes should be recovered (at least 12) and resection margins have to be free. Laparoscopic resection gives similar oncologic outcome compared to laparotomy and has less postoperative morbidity in experienced surgical hands.

Adjuvant chemotherapy is recommended for stages T1-4, N1-2, M0 (i.e. stage III, modified Dukes C1-3). In stage III colon cancer adjuvant chemotherapy significantly improves the disease-free survival (DFS) and overall survival [I, A]; the absolute survival benefit is approximately 15%. Adjuvant chemotherapy can be considered in selected node-negative patients, especially if high risk factors for recurrence are found.

The UK Quasar study that randomized patients postoperatively between no treatment and adjuvant 5-fluorouracil (5-FU) based therapy (mainly with leucovorin) has shown a small but statistically significant improvement in 5-year survival in unselected patients (mainly stage II).

Subgroup analyses of the stage II patients in the randomized studies comparing 5-FU/LV and 5-FU/LV/oxaliplatin (FOLFOX) suggests also an improved DFS in patients with high risk stage II colon cancer. Amongst the known high risk factors in stage II colon cancer are: T4, poorly differentiated adenocarcinoma/undifferentiated
carcinoma, vascular invasion, lymphatic vessel invasion, perineural invasion, obstruction or tumour perforation at initial presentation, ≤12 regional lymph nodes examined and high CEA level [II, B].

Recent evidence also showed the possible deleterious effect of 5-FU based chemotherapy in stage II tumours with microsatellite instability (MSI). It is therefore important to determine the MSI status in stage II colon cancer. Patients with low risk stage II colon cancer should not be offered adjuvant chemotherapy.

Standard adjuvant treatment consists of fluoropyrimidine-based chemotherapy which has shown a statistically significant survival benefit [I, A].

Options for adjuvant treatment include infusional 5-fluorouracil (5-FU)/LV-regimens without or with oxaliplatin and capcitabine with and without oxaliplatin. Capcitabine has been shown to be at least as effective and less toxic as bolus 5-FU/LV [I, A].

The combination of 5-FU/LV plus oxaliplatin significantly improves the DFS in high risk stage II and III colon cancer and improves also the overall survival in stage III colon cancer compared to 5-FU/LV [I].

The combination of a fluoropyrimidine plus oxaliplatin has therefore become the standard adjuvant treatment for stage III colon cancer in patients fit for combination chemotherapy [A]. The recommended duration of adjuvant chemotherapy is 6 months, starting as soon as the patent is recovered from the surgery and optimally within 6 weeks after the surgical intervention.

The adjuvant treatment after complete resection of metastatic disease is a specific situation addressed in ESMO clinical recommendations on advanced colorectal cancer.

A good correlation has been shown between the 3-year DFS and 5-year survival in the adjuvant treatment of colon cancer. Three-year DFS is therefore now considered as an appropriate endpoint in the adjuvant treatment of colon cancer [III].

**follow-up**

There is no strong proof that regular follow-up after successful treatment improves the outcome of patients with colorectal cancer.

However, it may be clinically beneficial to identify recurrence of colon cancer in a stage at which its diagnosis will have therapeutic implications (i.e. surgery for metastatic disease or for local recurrence).

In the absence of an evidence-based standard, a provisional recommendation to identify patients in need of salvage surgery and to prevent second colorectal cancers is the following:

- History and physical examination and CEA determination (if initially elevated) every 3–6 months for 3 years and every 6–12 months year 4 and 5 after surgery. Colonoscopy at year 1 and thereafter every 3 years to look for metachronous adenomas and cancers.
- CT scan of the chest and abdomen every 6 months for 3 years can be considered in patients who are higher risk for recurrence.
- Other laboratory and radiological examinations are of unproven benefit and shall be restricted to patients with suspicious symptoms.

**note**

Levels of evidence [I–V] and grades of recommendation [A–D] as used by the American Society of Clinical Oncology are given in square brackets. Statements without grading were considered justified standard clinical practice by the experts and the ESMO faculty.

**literature**


---

**Table 1. 2002-TNM system**

<table>
<thead>
<tr>
<th>TNM</th>
<th>Stage</th>
<th>Extension to organs</th>
<th>5-year overall survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tis No Mo</td>
<td>0</td>
<td>Carcinoma in situ</td>
<td>most likely normal</td>
</tr>
<tr>
<td>T1 No Mo</td>
<td>I</td>
<td>Mucosa or submucosa</td>
<td>&gt;90%</td>
</tr>
<tr>
<td>T2 No Mo</td>
<td>I</td>
<td>Muscularis propria</td>
<td>&gt;85%</td>
</tr>
<tr>
<td>T3 No Mo</td>
<td>IIa</td>
<td>Subserosa/periolic  tissue</td>
<td>&gt;80%</td>
</tr>
<tr>
<td>T4 No Mo</td>
<td>IIb</td>
<td>Perforation into visceral peritoneum or invasion of other organs</td>
<td>72%</td>
</tr>
<tr>
<td>T1-2 N1 Mo</td>
<td>IIIa</td>
<td>≤ 3 LN</td>
<td>60 – 83%</td>
</tr>
<tr>
<td>T3-4 N1 Mo</td>
<td>IIIb</td>
<td>= = 3 LN</td>
<td>42 – 64%</td>
</tr>
<tr>
<td>T1-4 N2 Mo</td>
<td>IIc</td>
<td>&gt; 4 LN</td>
<td>27 – 44%</td>
</tr>
<tr>
<td>Any T any N M1</td>
<td>IV</td>
<td>Distant metastases</td>
<td>&lt;10%</td>
</tr>
</tbody>
</table>
Staging provides essential prognostic information relevant for choosing adequate therapy and should also identify patients with resectable distant metastases. Labianca, R. (2010) Primary Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Adjuvant Treatment and Follow-Up. Annals of Oncology, 21, v70-v77. http://dx.doi.org/10.1093/annonc/mdq168. has been cited by the following article: TITLE: Comparative Study on Nigerian Wild and Edible Beans in Reversing Incidence of Colon Cancer in Albino Rats. AUTHORS: O. A. Awoyinka, A. Ileola, C. N. Imeoria, A. E. Omonisi, F. C. Oladele, M. F. Asaolu. KEYWORDS: Dextran Sodium Sulphate (DSS) Otili, Feregede, Pakala, Mucuna, Colon Cancer. JOURNAL NAME: Open Access Library Journal, Vol.3 No.7, July 11, ...Â Clinical Follow-Up Nursing Quality in Child Health. This eUpdate refers to the Early Colon Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, R. Labianca, B. Nordlinger, G. D. Beretta, S. Mosconi, M. MandalÂ, A. Cervantes, D. Arnold. Ann Oncol 2013; 24 (Suppl 6): vi64â€“vi72.Â The current standard of care for the adjuvant therapy in a stage III colon cancer is a combination of fluoropyrimidine and oxaliplatin. The benefit of these combinations has been demonstrated in three landmark trials: MOSAIC, NSABP C-07 and XELOXA, all of which showed significant improvement in disease-free survival (DFS) when compared with fluoropyrimidine single agent (reduction in risk of recurrence by 20%â€“23%).